Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2021 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.01B | $1.05B | $1.19B | $1.06B | $1.13B | $999M | $921M | $855M | $925M |
| Revenue growth | — | — | 4.1% | 13.6% | -10.8% | 7.0% | -12.0% | -7.8% | -7.2% | 8.3% |
| Gross profit | $650M | $826M | $868M | $989M | $873M | $926M | $805M | $744M | $693M | $724M |
| Gross margin | — | 82.1% | 82.9% | 83.1% | 82.3% | 81.6% | 80.6% | 80.8% | 81.1% | 78.3% |
| Operating income | $116M | $139M | $133M | $188M | $146M | $176M | $108M | $93.1M | $66.3M | $37.4M |
| Operating margin | — | 13.8% | 12.7% | 15.8% | 13.8% | 15.6% | 10.8% | 10.1% | 7.8% | 4.0% |
| Net income | $76.6M | $100M | $62.5M | $126M | $101M | $125M | $69.3M | $63.8M | $42.0M | $10.8M |
| Net margin | — | 9.9% | 6.0% | 10.6% | 9.5% | 11.0% | 6.9% | 6.9% | 4.9% | 1.2% |
| EPS (diluted) | $2.80 | $3.99 | $2.53 | $5.12 | $4.41 | $5.86 | $3.59 | $3.30 | $2.19 | $0.58 |
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2021 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $105M | $137M | $124M | $152M | $127M | $160M | $104M | $70.6M | $61.0M | $22.3M |
| Capital expenditures | $20.4M | $32.7M | $13.2M | $11.4M | $16.6M | $15.1M | $10.4M | $14.5M | $10.1M | $13.8M |
| Free cash flow | $84.8M | $104M | $111M | $141M | $110M | $145M | $93.5M | $56.1M | $50.9M | $8.53M |
| Share buybacks | $139M | $64.6M | $50.0M | $105M | $150M | $57.0M | $25.4M | $11.6M | $9.44M | $27.5M |
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2021 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $111M | $176M | $247M | $214M | $235M | $312M | $288M | $330M | $182M | $158M |
| Total assets | $351M | $471M | $519M | $554M | $517M | $641M | $597M | $633M | $748M | $743M |
| Total liabilities | — | — | — | — | — | — | — | $136M | $162M | $157M |
| Shareholders' equity | $230M | $325M | $363M | $391M | $352M | $442M | $434M | $497M | $532M | $533M |
| Retained earnings | $166M | $265M | $288M | $330M | $306M | $383M | $392M | $445M | $479M | $466M |
| Shares (wtd avg diluted) | 27.4M | 25.0M | 24.7M | 24.6M | 22.8M | 21.3M | 19.3M | 19.3M | 19.2M | 18.6M |
Every figure is extracted from USANA HEALTH SCIENCES INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.